ARTICLES BY ARNAUD DELADERIERE
-
![caution, precision-GettyImages-2149261776]( "In Vivo's Biggest Threat — Comparison To Old Models")
In Vivo's Biggest Threat — Comparison To Old Models1/23/2026In vivo CAR-T is not simply ex vivo without a manufacturing step. It is a different modality that relies on biological systems to regulate outcomes.
-
![vacation-GettyImages-1430503053]( "New Group Wants 'Phase-Appropriate' Thinking To Retire")
New Group Wants 'Phase-Appropriate' Thinking To Retire9/4/2025Decisions in cell and gene therapy are not about aligning with arbitrary clinical phases but about balancing risk.
Arnaud Deladeriere
Arnaud Deladeriere, Ph.D., is principal consultant at Cell&Gene Consulting Inc. Previously, he was head of MSAT and Manufacturing at Triumvira Immunologics, and before that, manufacturing manager at C3i. He received his Ph.D. in biochemistry from the University of Cambridge.